These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
962 related articles for article (PubMed ID: 25176136)
1. Ivabradine in stable coronary artery disease without clinical heart failure. Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R; N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136 [TBL] [Abstract][Full Text] [Related]
2. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Fox K; Ford I; Steg PG; Tendera M; Ferrari R; Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088 [TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844 [TBL] [Abstract][Full Text] [Related]
4. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L; Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500 [TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Fox K; Ferrari R; Tendera M; Steg PG; Ford I; Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146 [TBL] [Abstract][Full Text] [Related]
6. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R; Eur Heart J; 2015 Dec; 36(46):3291-6. PubMed ID: 26385957 [TBL] [Abstract][Full Text] [Related]
7. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K; Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction. Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice. Perings S; Stöckl G; Kelm M; Adv Ther; 2016 Sep; 33(9):1550-64. PubMed ID: 27432382 [TBL] [Abstract][Full Text] [Related]
10. Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention. Werdan K; Ebelt H; Nuding S; Höpfner F; Stöckl G; Müller-Werdan U Adv Ther; 2015 Feb; 32(2):120-37. PubMed ID: 25687888 [TBL] [Abstract][Full Text] [Related]
11. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the SIGNIFY trial. Grassi G Expert Opin Pharmacother; 2015; 16(12):1861-4. PubMed ID: 26153241 [TBL] [Abstract][Full Text] [Related]
13. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice. Bruguera Cortada J; Varela A Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882 [TBL] [Abstract][Full Text] [Related]
14. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L; Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495 [TBL] [Abstract][Full Text] [Related]
15. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease. Weeda ER; Nguyen E; White CM Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820 [TBL] [Abstract][Full Text] [Related]
16. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction. Perry CM Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944 [TBL] [Abstract][Full Text] [Related]
17. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study. Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004 [TBL] [Abstract][Full Text] [Related]
18. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R; Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635 [TBL] [Abstract][Full Text] [Related]
19. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials. Mengesha HG; Weldearegawi B; Petrucka P; Bekele T; Otieno MG; Hailu A BMC Cardiovasc Disord; 2017 Apr; 17(1):105. PubMed ID: 28454527 [TBL] [Abstract][Full Text] [Related]
20. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I; J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]